Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine
Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine
Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company’s TransVax™ therapeutic cytomegalovirus (CMV) vaccine.
Read more on News-Medical-Net
Categories: Breast Cancer Awareness Tags: advice, Phase, receives, Scientific, Therapeutic, TransVax, Trial, vaccine, Vical
Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
HALIFAX, NOVA SCOTIA–(Marketwire – Dec. 14, 2010) – Immunovaccine Inc. (TSX VENTURE:IMV) today announced preliminary safety results for its Phase I clinical trial of DPX-0907, a DepoVaxT-based therapeutic cancer vaccine candidate for the treatment of patients with advanced stage breast, ovarian or prostate cancer. In this trial, patients receive three subcutaneous injections of either 0.25 mL …
Read more on Marketwire
Categories: Breast Cancer Treatment Tags: Announces, cancer, Clinical, DPX0907, From, Immunovaccine, Phase, Preliminary, Results, Safety, Trial, vaccine
In Phase II Trial, Vaccine Extends Glioblastoma Patients’ Survival
In Phase II Trial, Vaccine Extends Glioblastoma Patients’ Survival
A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology…
Read more on Medical News Today
Categories: Breast Cancer Tumor Tags: Extends, glioblastoma, Patients, Phase, Survival, Trial, vaccine
Video: Brain Cancer Vaccine Promising
Video: Brain Cancer Vaccine Promising
Gliobastama is a particularly virulent form of brain cancer with a relatively low survival rate. But, Dr. Sanjay Gupta reports, a newly-developed vaccine may increase the life spans of patients.
Read more on CBS News
Advaxis Publishes Research On New Her2 Vaccine
Advaxis Publishes Research On New Her2 Vaccine
Scientists at Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print). “It has performed quite well in a number of preclinical models. We hope …
Read more on Medical News Today